

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A multivalent meningococcal bleb composition comprising a bleb preparation deficient in PorA in that it has less than 80% of the amount of PorA as compared to the same quantity of blebs made from strain H44/76 and a bleb preparation that is not deficient in PorA compared to blebs made from strain H44/76.
2. (Currently amended) The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype that is selected from among the most prevalent, the second most prevalent, the third most prevalent, and the fourth most prevalent serosubtypes in a country of use.
3. (Previously Presented) The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation deficient in PorA has less than 22% PorA of total bleb protein, or lacks PorA.
4. (Previously Presented) The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation not deficient in PorA has more than 28% PorA of total bleb protein.
5. (Previously Presented) The multivalent meningococcal bleb composition of claim 1, wherein the bleb preparation deficient in PorA is derived from the meningococcal CU-385 strain.
6. (Previously Presented) A vaccine for the treatment of neisserial disease comprising the multivalent meningococcal bleb composition of claim 1, and a pharmaceutically acceptable excipient.
7. (Previously Presented) The vaccine of claim 6 additionally comprising one or more plain or conjugated meningococcal capsular polysaccharides selected from the group of serogroups: A, C, Y and W.
8. (Previously Presented) The vaccine of claim 6 suitable for use in New Zealand or Europe wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.4.

9. (Previously Presented) The vaccine of claim 6 suitable for use in USA where the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.7,16.

10. (Previously Presented) The vaccine of claim 6 suitable for use in Norway wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype of P1.16.

11. (Withdrawn) A method of manufacturing the multivalent meningococcal bleb composition of claim 1 comprising the step of combining the bleb preparation that is not deficient in PorA with the bleb preparation that is deficient in PorA.

12. (Withdrawn) A method of preventing or treating neisserial-disease comprising the step of administering an immunologically effective amount of the vaccine of claim 6 to a host in need thereof.

13. (Withdrawn) The use of an immunologically effective amount of the vaccine of claim 6 in the manufacture of a medicament for the prevention or treatment of neisserial disease.

14. (Withdrawn) A method of manufacturing the vaccine of Claim 6 comprising the step of combining the bleb preparation that is not deficient in PorA with the bleb preparation that is deficient in PorA.

15. (New) The multivalent meningococcal bleb composition of claim 2, wherein the bleb preparation that is not deficient in PorA is derived from a meningococcal strain with a serosubtype that is the most prevalent in a country of use.